Just caught that a Glaukos director sold off fifteen thousand shares back in late January - dropped about $1.9M on the sale at $127.71 per share. That's actually a pretty solid chunk of his holdings, like 28% of what he directly owned. Afterward he was left with only around 37,000 shares worth like $4.7M.

What's interesting is this wasn't some random decision - it was all scheduled in advance through a 10b5-1 trading plan, so insiders setting up their sells ahead of time. The company's been having a rough time though, down almost 25% through 2025. They did get FDA approval for re-administering one of their glaucoma supplements recently, which maybe helped the stock bounce back a bit in January.

But here's the thing - Glaukos has been basically breaking even or losing money for years now. The insider selling combined with those losses makes you wonder if there's real confidence in a turnaround or if it's just people taking profits when they can. The stock's up a few percent so far this year, but those fundamentals are still pretty rough.